title: Testing for CHEK2 in the cancer genetics clinic: ready for prime time?
abstract: The 1100delC mutation of the CHEK2 gene was found to be a cause of breast cancer in 2002. The lifetime risk of breast cancer among women with a mutation and with a family history of breast cancer is approximately 25%. These women are good candidates for screening with MRI and for chemoprevention with tamoxifen. It is reasonable to test for this single mutation when women undergo testing for BRCA1 and BRCA2.
authors.affiliation: Womens College Research Institute, 790 Bay, Toronto, Ontario, Canada. Steven.narod@wchospital.ca
authors.forename: S A
authors.initials: SA
authors.lastname: Narod
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control*; D064447:Checkpoint Kinase 2; D018890:Chemoprevention / Q000379:methods; D005260:Female; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008403:Mass Screening; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D013629:Tamoxifen; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases